PRESS RELEASE 26. AUGUST 2015
New
Chief Executive
Officer at
NNE Pharmaplan
Jesper Kløve from Novo Nordisk succeeds
Morten Nielsen as CEO in the pharma
engineering company NNE Pharmaplan.
The change is a consequence of Novo Nordisk’s
planned investment in a new diabetes API plant
in USA.
NNE Pharmaplan’s present chief executive officer
Morten Nielsen has decided to leave the position in
order to move to North Carolina, USA, and manage
Novo Nordisk’s large investment project in a new
diabetes API plant, filling the position of Project Director
and Senior Vice President for diabetes API in USA.
Jesper Kløve thus takes up the position as new CEO
of the Novo Nordisk-owned engineering company
NNE Pharmaplan as of 1 September 2015. Jesper Kløve
is 49 years old and comes from a position at Novo
Nordisk as Senior Vice President of Device R&D where
he has been responsible for research and development
of the entire portfolio of devices since 2008. He has
been employed at Novo Nordisk since 2003 and has
held various management positions in the Novo group.
Lars Fruergaard Jørgensen concludes: ”I would like to
thank Morten Nielsen for the very positive development
that NNE Pharmaplan has gone through under his
leadership since 2011. Morten succeeded in cementing
NNE Pharmaplan as a stable and profitable business
and he has strengthened the company’s customer
focus. Today, NNE Pharmaplan is positioned as one of
the leading pharma engineering companies serving the
largest pharmaceutical businesses in the world. Jesper
Kløve’s task is now to continue the further business
development.”
FOR ADDITIONAL INFORMATION
Jesper Kløve, future CEO at NNE Pharmaplan :
+45 3075 6872, [email protected]
Mette Marqvard, Corporate Communication Manager
at NNE Pharmaplan: +45 3079 6066
[email protected]
”Jesper Kløve is a strong man in the position as new CEO
of NNE Pharmaplan,” says Lars Fruergaard Jørgensen,
chairman of NNE Pharmaplan’s board of directors and
Executive Vice President at Novo Nordisk. ”Jesper Kløve
has many years of management experience from global
companies and has brought about significant results
within the area of devices at Novo Nordisk where he
secured the launching of the insulin pens FlexTouch®
and NovoPen® 5 and established a strong portfolio of
new device units.”
NNE Pharmaplan is an international company specialised in pharma engineering. We help
pharmaceutical companies bring products to market by providing flexible, compliant and
future-proof solutions. We have close to 2,000 professionals delivering global knowledge
and best practices, all dedicated to supporting our customers globally and on local sites.
Through focused pharma engineering we enable our customers to deliver on demand.